Praxis (PRAX) director logs 11,600-share sale after option exercises
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Praxis Precision Medicines director Jill DeSimone reported a series of option-related trades in the company’s common stock. On June 24, 2026, she exercised options for a total of 11,600 shares at exercise prices of $44.25 and $147.30 per share, then sold 11,600 shares in multiple open-market transactions at weighted-average prices in the low $300s under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 10,903 Praxis common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 11,600 shares ($3,611,335)
Net Sell
16 txns
Insider
DeSimone Jill
Role
null
Sold
11,600 shs ($3.61M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,566 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 3,034 | $0.00 | -- |
| Exercise | Common Stock | 8,566 | $44.25 | $379K |
| Exercise | Common Stock | 3,034 | $147.30 | $447K |
| Sale | Common Stock | 10 | $301.44 | $3K |
| Sale | Common Stock | 120 | $303.127 | $36K |
| Sale | Common Stock | 320 | $305.31 | $98K |
| Sale | Common Stock | 683 | $306.767 | $210K |
| Sale | Common Stock | 1,240 | $308.243 | $382K |
| Sale | Common Stock | 999 | $309.383 | $309K |
| Sale | Common Stock | 1,750 | $310.889 | $544K |
| Sale | Common Stock | 2,854 | $311.914 | $890K |
| Sale | Common Stock | 1,004 | $312.83 | $314K |
| Sale | Common Stock | 504 | $313.663 | $158K |
| Sale | Common Stock | 1,279 | $314.901 | $403K |
| Sale | Common Stock | 837 | $315.705 | $264K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null);
Common Stock — 10,903 shares (Direct, null)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. This option was fully vested as of June 5, 2025. This option was fully vested as of May 23, 2025.
Key Figures
Shares sold: 11,600 shares
Options exercised: 11,600 shares
Exercise price: $44.25 per share
+3 more
6 metrics
Shares sold
11,600 shares
Total Praxis common shares sold in open-market transactions on June 24, 2026
Options exercised
11,600 shares
Total shares acquired via option exercise on June 24, 2026
Exercise price
$44.25 per share
Exercise price for options covering 8,566 shares
Exercise price
$147.30 per share
Exercise price for options covering 3,034 shares
Post-transaction holdings
10,903 shares
Praxis common shares directly owned after the final transaction
Sale price range
$302.50–$316.01 per share
Ranges cited in weighted-average price footnotes for multiple sale groups
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. The securities were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)... underlying security title: Common Stock"
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did Praxis (PRAX) director Jill DeSimone report?
Jill DeSimone reported exercising stock options and selling Praxis common shares. She exercised options for 11,600 shares and sold 11,600 shares in multiple open-market transactions on June 24, 2026, as disclosed in the Form 4 filing.
What stock options did Jill DeSimone exercise in this Praxis (PRAX) Form 4?
She exercised options covering 3,034 shares at an exercise price of $147.30 and 8,566 shares at an exercise price of $44.25. These exercises converted option awards into Praxis common shares before the reported sales.
What does the net effect of Jill DeSimone’s Praxis (PRAX) transactions indicate?
The filing shows 11,600 shares acquired through option exercises and 11,600 shares sold, resulting in a net-sell share count of 11,600 across open-market sales. The remaining 10,903 shares reflect her continued direct ownership position.